Key Stats for Ideaya Biosciences Stock
- Price change for Ideaya Biosciences stock: -10%
- $IDYA Share Price as of Jun. 9: $28
- 52-Week High: $39
- $IDYA Stock Price Target: $52
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Ideaya Biosciences (IDYA) stock dropped about 10% on Tuesday, with shares falling toward $27.
The catalyst was a classic biotech move that often hurts existing shareholders: a large stock offering. The company announced it intends to raise $300 million by selling shares and pre-funded warrants at $27 per share.
When a company sells stock below its recent trading price, investors in existing shares face dilution, meaning their ownership gets spread thinner. That’s what hit the stock.
The timing made it sting more.
- Ideaya Biosciences stock had climbed about 13% in the prior week on the back of strong data at the ASCO oncology conference.
- So the offering came right after a rally, which meant investors who bought the run-up felt the dilution most.
Analysts also trimmed their 2026 revenue forecasts and raised projected loss-per-share estimates, adding another layer of pressure on the stock.
See analysts’ growth forecasts and price targets for Ideaya Biosciences stock (It’s free) >>>
What the Market Is Telling Us About Ideaya Biosciences Stock
Here’s what makes this move frustrating for long-term holders: the underlying news is actually good.
- Citizens reiterated its Market Outperform rating with a $45 price target.
- The firm cited Ideaya’s expanding PRMT5 pipeline and a new collaboration with Roche to test the company’s next-generation drug IDE892 alongside Roche’s pan-RAS inhibitor in MTAP-deleted cancers.
- That deal also opens the door to a triplet combination with Ideaya’s MAT2A inhibitor.
The clinical data also hold up well.
- The Phase 2/3 trial of darovasertib in uveal melanoma showed a 37% response rate, compared with just 6% with standard care.
- The hazard ratio of 0.42 means a 58% reduction in risk of disease progression.
- The company has a breakthrough therapy designation and plans an expedited FDA filing.
So the fundamentals look solid. The drop is essentially about supply and dilution, not science.
The company needed capital to fund its pipeline, and raising $300 million provides a strong runway to do so.
With a current ratio above 10, Ideaya was already cash-rich, but this offering adds even more room to advance multiple trials across uveal melanoma, pancreatic cancer, and beyond.
For long-term investors watching Ideaya Biosciences stock, the average analyst target price near $50 still implies significant upside.
The market is reacting to the mechanics of dilution, not a change in the story.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Ideaya Biosciences Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
